MYELODYSPLASTIC SYNDROME (MDS)

The Myelodysplastic Syndrome (MDS) Panel is a specialized diagnostic test used to evaluate patients suspected of having Myelodysplastic Syndromes (MDS), a group of bone marrow disorders characterized by ineffective blood cell production and abnormal development of blood-forming cells.

In MDS, the bone marrow produces poorly formed or dysfunctional blood cells, leading to low counts of red blood cells, white blood cells, and/or platelets. Patients may experience symptoms such as fatigue, weakness, recurrent infections, easy bruising, or unexplained bleeding. Some forms of MDS can progress to Acute Myeloid Leukemia (AML), making early diagnosis and risk assessment essential.

The MDS evaluation often combines bone marrow examination, cytogenetic analysis, fluorescence in situ hybridization (FISH), flow cytometry, and molecular testing to identify chromosomal abnormalities and genetic changes associated with the disease.

The test helps establish the diagnosis, classify disease subtype, assess prognosis, and guide treatment planning.

Benefits of the Test

• Helps diagnose Myelodysplastic Syndromes
• Identifies chromosomal and genetic abnormalities
• Assists in disease classification and risk stratification
• Supports treatment planning and monitoring
• Helps evaluate progression risk to leukemia
• Provides important prognostic information

Why Doctors Recommend This Test

Doctors may recommend MDS testing for individuals with:

• Persistent unexplained anemia
• Low white blood cell counts
• Low platelet counts
• Abnormal complete blood count (CBC) results
• Suspected bone marrow disorders
• Unexplained fatigue or weakness
• Recurrent infections
• Easy bruising or bleeding
• Abnormal bone marrow findings

The test helps determine whether abnormal blood counts are caused by Myelodysplastic Syndrome or another hematological condition.

Preparation Before Test

Testing may require:

• Bone marrow aspirate and/or biopsy samples
• Peripheral blood samples
• Clinical history and laboratory reports
• Cytogenetic and molecular analysis when indicated

Preparation instructions depend on the type of sample being collected and the investigations ordered.

Normal Reporting Time

Reporting times vary depending on the tests performed:

• Bone marrow morphology: 3–7 working days
• Flow cytometry: 1–3 working days
• FISH studies: 3–7 working days
• Cytogenetics: 10–21 working days
• Molecular studies: 1–3 weeks

Who Should Take This Test?

• Patients with unexplained cytopenias
• Individuals with suspected MDS
• Patients with abnormal bone marrow findings
• Individuals requiring hematology evaluation
• Patients undergoing leukemia risk assessment
• People referred by hematologists or oncologists

The MDS Panel is an essential diagnostic tool that helps physicians accurately diagnose, classify, and manage Myelodysplastic Syndromes.

Clinical Significance

The test may help identify:

• Myelodysplastic Syndromes (MDS)
• Refractory anemia
• Refractory cytopenias
• MDS with excess blasts
• MDS with ring sideroblasts
• Clonal chromosomal abnormalities
• Bone marrow dysplasia
• Risk of progression to Acute Myeloid Leukemia (AML)

Common chromosomal abnormalities associated with MDS include:

• Del(5q)
• Monosomy 7
• Del(7q)
• Trisomy 8
• Del(20q)
• Complex karyotypic abnormalities

These findings play a major role in prognosis and treatment selection.